Tag Archives: BIO CEO

#BIOBuyside Twitter Chat: What Do Biotech Investors Expect in 2014?

Dave Thomas

Is 2014 a good time to invest in biotech? How many biotech IPOs will there be? Which sectors will perform the best? To find out what investors think about these questions and more, BIO is conducting its annual Buy-side Investor Perception Survey and releasing the results at the 16th Annual BIO CEO & Investor Conference in New York, Monday Feb. 10. But as the results are coming in, BIO is hosting the #BIOBuyside Twitter chat Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,

What’s In Store for Biotechs at this Year’s CEO & Investor Conference

CEO2014_blog copy

In just a few weeks, industry leaders will gather in New York for one of BIO’s largest and most successful events, the 16th Annual BIO CEO & Investor Conference. As we’ve seen at JPMorgan, the extraordinary performance of biotech equities for the past several years has generated a great deal of interest among investors to work with biotech companies to foster innovation in the coming year. This year’s event is shaping up to be even Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,

BIO White Paper Highlights Key Industry Legislation and its Impact on the Industry


Innovative biotech companies at all stages of the development process are working toward next generation technologies to heal, fuel, and feed the world. In an effort to highlight promising policy legislation and its impact on the biotech sector, BIO has authored the following white paper: The Future Policy Landscape for Emerging Biotechnology Companies. Many research-intensive companies rely on private investment to support their groundbreaking R&D. Therefore, favorable legislation such as the JOBS Act is essential Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Show Me the Money: Reimbursement in an ACA World

BIO CEO 2013

A panel at the BIO CEO & Investor Conference focused on reimbursement discussed value from a variety of perspectives and agreed that the landscape is shifting dramatically. The reimbursement roundtable featured payors, providers, and other stakeholders discussing Affordable Care Act (ACA) implementation and the wider reimbursement landscape. With many key provisions of the ACA slated to take effect in 2013 and beyond, the industry is facing sweeping changes to the managed care and reimbursement road map. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Orphan Drugs: Making Rare Diseases Rarer


A panel at the BIO CEO & Investor Conference provided an analysis of the thriving orphan drug market opportunity featuring industry, clinical and regulatory experts specializing in rare diseases. The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,